The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
Matthew S. Block(Mayo Clinic in Arizona), Akseli Hemminki(Biocenter Finland)
Cited by 26
Related Papers
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus
|Molecular Therapy|2003|172
An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene Expression
|Molecular Therapy|2001|127
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
|Clinical Cancer Research|2018|97